Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 7/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26093155 | 1.00 | MAT2A (0.41) | MAT2APDE10AKDM4EMAPTGRIN1 | |
| SCHEMBL26485641 | 0.88 | MAT2A (0.39) | MAT2APDE10AKDM4E | |
| SCHEMBL31026800 | 0.88 | MAT2A (0.39) | MAT2APDE10AKDM4E | |
| SCHEMBL31026802 | 0.84 | MAT2A (0.56) | MAT2AKDM4EMAPTGRIN1GRIN2B | |
| SCHEMBL26485640 | 0.84 | MAT2A (0.56) | MAT2AKDM4EMAPTGRIN1GRIN2B | |
| SCHEMBL30418873 | 0.76 | MAT2A (0.50) | MAT2APDE10A | |
| SCHEMBL26485128 | 0.76 | MAT2A (0.50) | MAT2APDE10A | |
| SCHEMBL30420490 | 0.75 | MAT2A (0.40) | MAT2AKDM4E | |
| SCHEMBL27204011 | 0.75 | MAT2A (0.40) | MAT2AKDM4E | |
| SCHEMBL30420438 | 0.75 | MAT2A (0.41) | MAT2APDE10AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042890-A1 | METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2025-02-06 | — | — | US | disclosed |
| EP-4419506-A1 | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2024-08-28 | — | — | EP | disclosed |
| CN-118434722-A | Methionine adenosyltransferase 2A (MAT 2A) inhibitors and uses thereof | 英矽智能科技知识产权有限公司 | 2024-08-02 | — | — | CN | disclosed |
| WO-2023066283-A1 | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042890-A1 | METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF | MAT2A, MAT2B, MAT1A | MAT2A 1/4885PDE10A 1237/4885KDM4E 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.